| # | Title | Journal | Year | Citations |
|---|
| 1 | Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products | Journal of Pharmaceutical and Biomedical Analysis | 2008 | 519 |
| 2 | The IL-23/T17 pathogenic axis in psoriasis is amplified by keratinocyte responses | Trends in Immunology | 2013 | 399 |
| 3 | Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products | Journal of Immunological Methods | 2008 | 326 |
| 4 | Mutational landscape of gastric adenocarcinoma in Chinese: Implications for prognosis and therapy | Proceedings of the National Academy of Sciences of the United States of America | 2015 | 137 |
| 5 | A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial | Annals of Oncology | 2015 | 132 |
| 6 | Prevalence of RAS mutations and individual variation patterns among patients with metastatic colorectal cancer: A pooled analysis of randomised controlled trials | European Journal of Cancer | 2015 | 127 |
| 7 | Absence of functional EpoR expression in human tumor cell lines | Blood | 2010 | 90 |
| 8 | Mouse Models for Assessing Protein Immunogenicity: Lessons and Challenges | Journal of Pharmaceutical Sciences | 2016 | 88 |
| 9 | Targeted Next Generation Sequencing as a Reliable Diagnostic Assay for the Detection of Somatic Mutations in Tumours Using Minimal DNA Amounts from Formalin Fixed Paraffin Embedded Material | PLoS ONE | 2016 | 79 |
| 10 | The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications | Clinical Cancer Research | 2017 | 71 |
| 11 | Guideline on the requirements of external quality assessment programs in molecular pathology | Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin | 2013 | 70 |
| 12 | Development of a Maturing T-Cell-Mediated Immune Response in Patients with Idiopathic Parkinson’s Disease Receiving r-metHuGDNF Via Continuous Intraputaminal Infusion | Journal of Clinical Immunology | 2007 | 64 |
| 13 | Cross-Study Homogeneity of Psoriasis Gene Expression in Skin across a Large Expression Range | PLoS ONE | 2013 | 57 |
| 14 | Prospective–retrospective biomarker analysis for regulatory consideration: white paper from the industry pharmacogenomics working group | Pharmacogenomics | 2011 | 45 |
| 15 | The development and validation of a sensitive, dual-flow cell, SPR-based biosensor immunoassay for the detection, semi-quantitation, and characterization of antibodies to darbepoetin alfa and epoetin alfa in human serum | Journal of Pharmaceutical and Biomedical Analysis | 2009 | 41 |
| 16 | Detection of QTc interval prolongation using jacket telemetry in conscious non‐human primates: comparison with implanted telemetry | British Journal of Pharmacology | 2014 | 37 |
| 17 | Pharmacokinetic and Pharmacodynamic Relationship of AMG 811, An Anti-IFN-γ IgG1 Monoclonal Antibody, in Patients with Systemic Lupus Erythematosus | Pharmaceutical Research | 2015 | 34 |
| 18 | Assessment of immunogenicity of romiplostim in clinical studies with ITP subjects | Annals of Hematology | 2010 | 28 |
| 19 | Preclinical development of AMG 139, a human antibody specifically targeting IL‐23 | British Journal of Pharmacology | 2015 | 26 |
| 20 | First-In-Human Study Of AMG 319, a Highly Selective, Small Molecule Inhibitor Of PI3Kδ, In Adult Patients With Relapsed Or Refractory Lymphoid Malignancies | Blood | 2013 | 26 |
| 21 | Analysis of KRAS/NRAS mutations in phase 3 study 20050181 of panitumumab (pmab) plus FOLFIRI versus FOLFIRI for second-line treatment (tx) of metastatic colorectal cancer (mCRC). | Journal of Clinical Oncology | 2014 | 24 |
| 22 | Performance of the pegfilgrastim on-body injector as studied with placebo buffer in healthy volunteers | Current Medical Research and Opinion | 2017 | 21 |
| 23 | Impact of Precipitation of Antibody Therapeutics After Subcutaneous Injection on Pharmacokinetics and Immunogenicity | Journal of Pharmaceutical Sciences | 2019 | 21 |
| 24 | Clinical immunogenicity of the d -amino acid peptide therapeutic etelcalcetide: Method development challenges and anti-drug antibody clinical impact assessments | Journal of Immunological Methods | 2017 | 17 |
| 25 | Prediction of clinical pharmacokinetics of AMG 181, a human anti‐ α 4 β 7 monoclonal antibody for treating inflammatory bowel diseases | Pharmacology Research and Perspectives | 2015 | 16 |
| 26 | Differentially regulated functional gene clusters identified during ischemia and reperfusion in isolated cardiac myocytes using coverslip hypoxia | Journal of Pharmacological and Toxicological Methods | 2008 | 12 |
| 27 | Chemical and Biophysical Characteristics of Monoclonal Antibody Solutions Containing Aggregates Formed during Metal Catalyzed Oxidation | Pharmaceutical Research | 2017 | 12 |
| 28 | A clinical therapeutic protein drug–drug interaction study: coadministration of denosumab and midazolam in postmenopausal women with osteoporosis | Pharmacology Research and Perspectives | 2014 | 11 |
| 29 | High-throughput screening of hybridoma supernatants using multiplexed fluorescent cell barcoding on live cells | Journal of Immunological Methods | 2017 | 11 |
| 30 | Utility of a Bayesian Mathematical Model to Predict the Impact of Immunogenicity on Pharmacokinetics of Therapeutic Proteins | AAPS Journal | 2016 | 9 |
| 31 | Statistical and Bioanalytical Considerations for Establishing a Depletion Criterion for Specificity Testing During Immunogenicity Assessment of a Biotherapeutic | AAPS Journal | 2013 | 6 |
| 32 | Dose-related Differences in the Pharmacodynamic and Toxicologic Response to a Novel Hyperglycosylated Analog of Recombinant Human Erythropoietin in Sprague-Dawley Rats with Similarly High Hematocrit | Toxicologic Pathology | 2014 | 6 |
| 33 | Prognostic impact of tumor MET expression among patients with stage IV gastric cancer: a Danish cohort study | Annals of Epidemiology | 2016 | 6 |
| 34 | Challenges in Developing a Validated Biomarker for Angiogenesis Inhibitors: The Motesanib Experience | PLoS ONE | 2014 | 6 |
| 35 | Trends in characteristics and outcomes among US adults hospitalised with COVID-19 throughout 2020: an observational cohort study | BMJ Open | 2022 | 6 |
| 36 | Maximizing the Impact of Physiologically Based Oral Absorption Modeling and Simulation | Journal of Pharmaceutical Sciences | 2017 | 5 |
| 37 | Clinical Implications and Translation of an Off-Target Pharmacology Profiling Hit: Adenosine Uptake Inhibition In Vitro | Translational Oncology | 2019 | 5 |
| 38 | Detection of MET amplification in gastroesophageal tumor specimens using IQFISH | Annals of Translational Medicine | 2017 | 5 |
| 39 | Prognostic impact of tumor MET expression among patients with stage IV gastric cancer: A Danish cohort study. | Journal of Clinical Oncology | 2014 | 4 |
| 40 | SRM-based measurements of proprotein convertase subtilisin/kexin type 9 and lipoprotein(a) kinetics in nonhuman primate serum | Bioanalysis | 2016 | 3 |
| 41 | Specific Method Validation and Sample Analysis Approaches for Biocomparability Studies of Denosumab Addressing Method and Manufacture Site Changes | AAPS Journal | 2013 | 2 |
| 42 | Modeling the pharmacokinetic‐pharmacodynamic relationship of the monoclonal anti‐macaque‐ IL ‐15 antibody Hu714Mu XH u in cynomolgus monkeys | Pharmacology Research and Perspectives | 2015 | 2 |
| 43 | MET deletion is a frequent event in gastric/gastroesophageal junction/esophageal cancer: a cross-sectional analysis of gene status and signal distribution in 1,580 patients | Annals of Translational Medicine | 2021 | 2 |
| 44 | AMG 900, a Potent and Highly Selective Aurora Kinase Inhibitor Shows Promising Preclinical Activity Against Acute Myeloid Leukemia Cell Lines In Vitro and In Vivo | Blood | 2013 | 2 |
| 45 | Cytokines Associated with Increased Erythropoiesis in Sprague-Dawley Rats Administered a Novel Hyperglycosylated Analog of Recombinant Human Erythropoietin | Toxicologic Pathology | 2014 | 1 |
| 46 | Prevalence of RAS mutations among patients with metastatic colorectal cancer by country and region in randomized clinical trials: A pooled analysis. | Journal of Clinical Oncology | 2015 | 1 |
| 47 | Exploratory RAS analysis of the phase Ib/II 20060447 trial of rilotumumab (R) or ganitumab (G) plus panitumumab (pmab) versus pmab alone in patients (pts) with previously treated metastatic colorectal cancer (mCRC). | Journal of Clinical Oncology | 2015 | 0 |
| 48 | Amphiregulin (AREG) expression and response to first-line panitumumab (pmab) plus FOLFIRI in metastatic colorectal cancer (mCRC). | Journal of Clinical Oncology | 2015 | 0 |
